Editorial
Re-examining the Cardiovascular Therapeutic Benefits of Aspirin
Abstract
Although originally touted to have no effect on the heart, aspirin indeed exerts cardiovascular therapeutic benefits. Aspirin has been shown to reduce the risk of a first myocardial infarction (MI) by one-third. Evidence suggests that a more widespread and appropriate use of aspirin in men and women would reduce the burden of cardiovascular disease in our country by preventing more than 150,000 premature deaths per year.1 However, despite clinical trial evidence and guideline recommendations, it is estimated that only a portion of patients who would benefit from aspirin actually receive the therapy.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1.Eidelman RS, Herbert PR, Weisman SM, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003;163:2006–2010.
2.The Steering Committee for the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ health study. N Engl J Med 1989;321:129–135.
3.Peto R, Gray R, Collins R, et al. Randomized trial of phphylactic daily aspirin in British male doctors. BMJ 1988;296:313–316.
4.The Medical Research Council’s General Practice Research Framework. Thrombosis Prevention Trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233–241.
5.Hannson L, Zanchetti A, Carruthers SG, et al; for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755–1762.
6.Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001;357:89–95.
7.Ridker PM, Cook NR, Lee MI, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1304.
8.Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306–313.
9.Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;136:161–172.
10.Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: concensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106:388–391.
11.Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease; the seventh ACCP conference on antithrombotic and thrombolytic therapy. CHEST 2004; 126(Suppl 3):S513–S548.
12.Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular disease in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162–172.
13.Mosca L, Banka CL, Benjamin EJ, et al. Evidence based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007;115:1481–1501.
